Zealand Pharma Sets Record in C25 Index

Zealand Pharma’s share price dramatically rose by 35.7% at Monday’s market close, the largest single-day percentage jump in the C25 index since its creation on December 18, 2017. The spike happened after promising results from its treatment for fatty liver, Survodutid, which improved health in 83% of patients versus 18.2% in a placebo group. Fatty liver is the most common liver disease globally and can be dangerous if it leads to inflammation. The company’s stock price has surged around 190% over the past year. Survodutid, developed with Boehringer Ingelheim, is part of a phase 2 study and is also being assessed as a potential obesity treatment. Zealand Pharma joined the C25 index at the end of 2023, replacing FLSmidth and Netcompany.